Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.73 |
| ▸ | PKM | P14618 | 1/20 | 0.73 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.67 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.67 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26388870 | 0.92 | MEN1 (0.62) | MEN1KMT2APKMSIRT2PDCD1 | |
| SCHEMBL786246 | 0.89 | PDCD1 (0.81) | MEN1KMT2APKMSIRT2PDCD1 | |
| SCHEMBL14855807 | 0.88 | SIRT2 (0.78) | MEN1KMT2APKMSIRT2PDCD1 | |
| SCHEMBL882567 | 0.85 | MEN1 (0.76) | MEN1KMT2APKMRAB9ANPC1 | |
| SCHEMBL30932523 | 0.85 | RXFP1 (0.73) | ALDH1A1LMNA | |
| SCHEMBL4766874 | 0.85 | RXFP1 (0.73) | ALDH1A1LMNA | |
| SCHEMBL882472 | 0.84 | RAB9A (0.67) | MEN1KMT2ARAB9ANPC1POLB | |
| SCHEMBL2029098 | 0.84 | MEN1 (1.00) | MEN1KMT2APKMRAB9ANPC1 | |
| SCHEMBL16211079 | 0.84 | NPC1 (0.64) | PDCD1CD274RAB9ANPC1KDM4E | |
| SCHEMBL24489084 | 0.83 | MAPK14 (0.64) | MEN1KMT2APKMSIRT2PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183236-B2 | Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183236-B2 | Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2012-05-22 | — | — | US | disclosed |
| US-20090088420-A1 | COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-04-02 | — | — | US | disclosed |
| US-20090088420-A1 | COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088420-A1 | COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS | TYMP, IMPDH1, SAMHD1 | MEN1 4601/4885KMT2A 1477/4885PKM 2456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.